Willow Biosciences Inc (WLLW) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Willow Biosciences Inc (WLLW) has a cash flow conversion efficiency ratio of 0.055x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-38.00K ≈ $-27.49K USD) by net assets (CA$-690.00K ≈ $-499.14K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Willow Biosciences Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Willow Biosciences Inc - Cash Flow Conversion Efficiency Trend (2000–2024)
This chart illustrates how Willow Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Willow Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Willow Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tatton Asset Management plc
LSE:TAM
|
0.130x |
|
GRAND PEAK CAPITAL
F:6GP1
|
-0.012x |
|
YGL Convergence Bhd
KLSE:0086
|
0.001x |
|
COINSILIUM GROUP LTD
F:5CT
|
N/A |
|
THOR MNG CUFS/1LS- 00001
F:T5MB
|
N/A |
|
Top KingWin Ltd
NASDAQ:WAI
|
-0.006x |
|
CaliberCos Inc. Class A Common Stock
NASDAQ:CWD
|
-0.173x |
|
Boku Inc
LSE:BOKU
|
0.369x |
Annual Cash Flow Conversion Efficiency for Willow Biosciences Inc (2000–2024)
The table below shows the annual cash flow conversion efficiency of Willow Biosciences Inc from 2000 to 2024. For the full company profile with market capitalisation and key ratios, see Willow Biosciences Inc (WLLW) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$-505.00K ≈ $-365.31K |
CA$-3.72 Million ≈ $-2.69 Million |
7.372x | +331.97% |
| 2023-12-31 | CA$3.44 Million ≈ $2.49 Million |
CA$-10.92 Million ≈ $-7.90 Million |
-3.178x | -275.40% |
| 2022-12-31 | CA$16.37 Million ≈ $11.84 Million |
CA$-13.86 Million ≈ $-10.03 Million |
-0.847x | -37.86% |
| 2021-12-31 | CA$29.68 Million ≈ $21.47 Million |
CA$-18.23 Million ≈ $-13.19 Million |
-0.614x | -102.69% |
| 2020-12-31 | CA$-559.00K ≈ $-404.37K |
CA$-12.78 Million ≈ $-9.24 Million |
22.862x | +5592.30% |
| 2019-12-31 | CA$22.01 Million ≈ $15.92 Million |
CA$-9.16 Million ≈ $-6.63 Million |
-0.416x | +73.93% |
| 2018-12-31 | CA$835.03K ≈ $604.05K |
CA$-1.33 Million ≈ $-964.33K |
-1.596x | -143.05% |
| 2017-12-31 | CA$-145.01K ≈ $-104.90K |
CA$-537.68K ≈ $-388.95K |
3.708x | +10.99% |
| 2016-12-31 | CA$-383.33K ≈ $-277.30K |
CA$-1.28 Million ≈ $-926.41K |
3.341x | +876.08% |
| 2015-12-31 | CA$1.01 Million ≈ $728.19K |
CA$-433.34K ≈ $-313.47K |
-0.430x | +3.17% |
| 2014-12-31 | CA$1.38 Million ≈ $999.85K |
CA$-614.45K ≈ $-444.48K |
-0.445x | +30.69% |
| 2013-12-31 | CA$1.44 Million ≈ $1.04 Million |
CA$-921.19K ≈ $-666.37K |
-0.641x | -502.05% |
| 2012-12-31 | CA$901.49K ≈ $652.12K |
CA$-96.04K ≈ $-69.48K |
-0.107x | +52.32% |
| 2011-12-31 | CA$2.53 Million ≈ $1.83 Million |
CA$-564.70K ≈ $-408.49K |
-0.223x | +9.07% |
| 2010-12-31 | CA$3.52 Million ≈ $2.55 Million |
CA$-865.76K ≈ $-626.28K |
-0.246x | -44.84% |
| 2009-12-31 | CA$5.24 Million ≈ $3.79 Million |
CA$-889.16K ≈ $-643.20K |
-0.170x | +36.10% |
| 2008-12-31 | CA$3.47 Million ≈ $2.51 Million |
CA$-922.61K ≈ $-667.40K |
-0.266x | +39.98% |
| 2007-12-31 | CA$2.50 Million ≈ $1.81 Million |
CA$-1.11 Million ≈ $-799.41K |
-0.442x | -104.59% |
| 2006-12-31 | CA$-21.98K ≈ $-15.90K |
CA$-211.79K ≈ $-153.21K |
9.634x | +1974.10% |
| 2005-12-31 | CA$-109.44K ≈ $-79.17K |
CA$-50.84K ≈ $-36.77K |
0.465x | +121.24% |
| 2004-12-31 | CA$-714.97K ≈ $-517.20K |
CA$-150.11K ≈ $-108.59K |
0.210x | +37667.14% |
| 2002-12-31 | CA$-674.55K ≈ $-487.96K |
CA$-375.00 ≈ $-271.27 |
0.001x | +219.56% |
| 2001-12-31 | CA$-604.35K ≈ $-437.18K |
CA$281.00 ≈ $203.27 |
0.000x | -100.19% |
| 2000-12-31 | CA$-441.04K ≈ $-319.04K |
CA$-105.17K ≈ $-76.08K |
0.238x | -- |
About Willow Biosciences Inc
Willow Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical products in the United States. The company has licensing and development partnership with Laurus Labs to develop and commercialize active pharmaceutical ingredients and other ingredients. Willow Biosciences Inc. was founded in 20… Read more